Tamoxifen citrate (Business Opportunities - Marketing & Sales)

Hot-Web-Ads > Business Opportunities > Marketing & Sales

Item ID 16146432 in Category: Business Opportunities - Marketing & Sales

Tamoxifen citrate


Free Online Advertising
Free Internet Web Site Advertising.


UK Free Classifieds
United Kingdom Free Ads Website.
100% Free Ad Posting.


Canada Free Ads
Popular Online Classifieds in Canada.
No Sign up, No Email Required to Post.

Tamoxifen citrate is a non-steroidal compound with structural similarities to diethylstilbestrol. Tamoxifen citrate is an estrogen receptor antagonist/partial agonist. Induces oxidative stress and apoptosis in estrogen receptor-negative cancer cell lines. Displays neuroprotective effects in permanent focal ischemia. Inhibits PKC. Potent agonist at GPR30 (membrane estrogen receptor). Clinically useful breast cancer agent.
Tamoxifen is used for the treatment of invasive breast cancer in men and women, the most common type of breast cancer, following surgery and/or radiation and for preventing invasive breast cancer in women at high risk for developing it. Tamoxifen also is used for the treatment of women following surgery and radiation for a less common type of breast cancer called ductal carcinoma in situ (DCIS or Intraductal Carcinoma). Women who have had DCIS are at high risk for developing invasive breast cancer at a later date, and tamoxifen prevents development of the invasive cancer in almost half of the women during the first five years of treatment. Occasionally, tamoxifen is used to stimulate ovulation.
Brand: Soarwin
CAS No.: 54965-24-1
EC Number: 259-415-2
Molecular Formula: C32H37NO8
Melting point: 140-144 °C

Related Link: Click here to visit item owner's website (0 hit)

Target State: All States
Target City : All Cities
Last Update : Aug 06, 2025 2:54 AM
Number of Views: 37
Item  Owner  : Anna
Contact Email:
Contact Phone: +86 19944061337

Friendly reminder: Click here to read some tips.
Hot-Web-Ads > Business Opportunities > Marketing & Sales
 © 2025 Hot-Web-Ads.com
2025-08-29 (0.292 sec)